Chemomab Therapeutics Ltd. (CMMB) Thursday announced positive results from the Phase 2 SPRING trial of monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis. The results show a proof-of-concept for CM-101, the company claimed.
The company said the trial with CM-101 achieved its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across a broad range of secondary efficacy endpoints. The data also showed statistically significant improvement in liver stiffness, a key marker.
The double-blind placebo-controlled SPRING study assessed 10 mg/kg and 20 mg/kg doses of CM-101.
Dose-dependent responses were observed for multiple disease-related biomarkers. Primary Endpoint
Chemomab said it is preparing for an End-of-Phase 2 meeting with the FDA to discuss the SPRING trial results and the design of a proposed Phase 3 PSC trial.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.